Colgate-Palmolive insider plans sale of 45,568 shares

Colgate-Palmolive reported a planned sale of 45,568 shares of its common stock under a Rule 144 notice, with an aggregate market value of $4,279,497.44.

Rhea-AI Filing Summary

Colgate-Palmolive reported a planned sale of 45,568 shares of its common stock under a Rule 144 notice, with an aggregate market value of $4,279,497.44. The shares are to be sold through Merrill Lynch on the NYSE around 02/04/2026.

The securities were acquired through vesting of performance share unit awards from Colgate-Palmolive in February and September 2024, granted as part of the issuer’s equity compensation plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Colgate-Palmolive (CL) disclose in this Form 144 filing?

The filing discloses a planned sale of 45,568 Colgate-Palmolive common shares under Rule 144. The shares are proposed to be sold on the NYSE through Merrill Lynch, reflecting an aggregate market value of $4,279,497.44.

How many Colgate-Palmolive (CL) shares are planned for sale and what is their value?

The notice covers a planned sale of 45,568 common shares of Colgate-Palmolive. The aggregate market value listed is $4,279,497.44, based on the market price used in the Form 144 disclosure.

When are the Colgate-Palmolive (CL) shares expected to be sold under this notice?

The approximate date of sale stated is 02/04/2026. The transaction is to be executed on the New York Stock Exchange (NYSE) through Merrill Lynch, according to the information provided in the notice.

How were the Colgate-Palmolive (CL) shares in this Form 144 acquired?

The shares were acquired via vesting of performance share unit awards from Colgate-Palmolive. Vesting dates include 02/15/2024, 02/18/2024, and 09/13/2024, with each batch granted under the issuer’s equity compensation plan.

Which broker and exchange are involved in this Colgate-Palmolive (CL) planned sale?

The planned sale will be executed through Merrill Lynch, located at 225 Liberty Street in New York. The shares are intended to be sold on the NYSE, as specified in the Form 144 disclosure.

How many Colgate-Palmolive (CL) shares are outstanding in this Form 144 disclosure?

The document lists 806,064,942 shares of Colgate-Palmolive common stock as outstanding. This provides a baseline for understanding the size of the planned 45,568-share sale relative to the total share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001464265
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	COLGATE PALMOLIVE CO
SEC File Number	001-00644
Address of Issuer	300 PARK AVE NEW YORK NEW YORK 10022
Phone	2123102000
Name of Person for Whose Account the Securities are To Be Sold	Wallace Noel R.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	45568	4279497.44	806064942	02/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/15/2024	Vesting of performance share unit award	COLGATE PALMOLIVE CO			26844	02/15/2024	Granted as part of issuer equity compensation plan
Common Stock	02/18/2024	Vesting of performance share unit award	COLGATE PALMOLIVE CO			14470	02/18/2024	Granted as part of issuer equity compensation plan
Common Stock	09/13/2024	Vesting of performance share unit award	COLGATE PALMOLIVE CO			4254	09/13/2024	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Noel Wallace
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)